Medical Xpress

JANUARY 27, 2023

COVID vaccines call our immune systems to action, generating antibodies which fight against any contact we have with the virus. Antibodies help to reduce the effects of an infection or even prevent it altogether. Scientists have estimated that vaccination has averted millions of COVID deaths worldwide.

Vaccination 98

Vaccination Vaccine Antibody Scientist 98

pharmaphorum

FEBRUARY 25, 2021

Pfizer/BioNTech’s mRNA vaccine against COVID is a technical marvel – but the ultra-cool temperatures required for storage and stability has been tricky to handle. The company announced a phase 1 trial is beginning of its nasal spray vaccine just as scientists in the UK said they are considering a similar approach.

Vaccination 111

Vaccination Vaccine Immune Response Trials 111

pharmaphorum

JANUARY 15, 2021

J&J has announced early trial results that suggest its single-shot coronavirus vaccine provides a sustained response against the virus ahead of a phase 3 trial readout due later this month. Both of these vaccines require two doses, as does the most recently approved shot from Moderna, which is due to arrive in the UK in the spring.

Vaccination 119

Vaccination Vaccine Immune Response Antibody 119

Scienmag

MARCH 5, 2021

Scientists at Walter Reed Army Institute of Research, in a collaboration the Duke University, have confirmed that monoclonal antibodies can be an effective tool in the global fight against malaria.

Scientist 74

Scientist Antibody Research Allergies 74

pharmaphorum

MARCH 9, 2021

Last year, Belgium’s ExeVir Bio raised 23 million euros ($27 million) to finance development of llama antibodies – and now it is ready to begin clinical development of a potential treatment that could be effective against emerging COVID-19 variants. ExeVir is not the first company to spin out of VIB to focus on camelid antibodies.

Antibody 98

Antibody Life Science Scientist Development 98

Scienmag

DECEMBER 23, 2021

Credit: Julianna Han, Ward Lab at Scripps Research LA JOLLA, CA—Scientists at Scripps Research, University of Chicago and Icahn School of Medicine at Mount Sinai have identified a new Achilles’ heel of influenza virus, making progress in the quest for a universal flu vaccine.

Vaccination 96

Vaccination Vaccine Research Antibody 96

pharmaphorum

JULY 27, 2021

Boehringer Ingelheim’s latecomer antibody therapy for COVID-19 has been side-lined, as the company focuses its attention on its thrombolytic drug alteplase, heading into a phase 3 programme later this year. The hope was that an inhaled antibody would reach higher levels in the lung, where it is most needed, than systemic antibodies.

Antibody 98

Antibody Clinical Development Development Scientist 98

Scienmag

FEBRUARY 4, 2022

million people, with no vaccine in sight. However, a new study by researchers at The Wistar Institute, an international biomedical research leader in cancer, immunology, infectious disease, and vaccine development, takes a promising step in the direction of developing […]. PHILADELPHIA — (Feb.

Vaccination 81

Vaccination Vaccine Development Research 81

pharmaphorum

JANUARY 20, 2021

Laboratory studies have confirmed that antibodies stimulated by Pfizer and BioNTech’s COVID-19 vaccine can neutralise the new, more transmissible variant of SARS-CoV-2 identified in the UK. That suggests that patients could get SARS-CoV-2 twice, but also that the current crop of vaccines may not be as effective.

Vaccination 98

Vaccination Vaccine Antibody Protein 98

pharmaphorum

NOVEMBER 25, 2022

Scientists in the US say they have developed an mRNA-based vaccine that encompasses all 20 known subtypes of influenza that could form the basis of a future universal jab. The goals of the programme are also similar to those in COVID vaccine development.

Vaccination 105

Vaccination Vaccine Research Immune Response 105

pharmaphorum

JUNE 30, 2021

Just a few months after starting clinical trials of its nasal spray vaccine for COVID-19, US biotech Altimmune is abandoning the project, saying that it generated weaker than expected immune responses in a phase 1 trial. . The post Altimmune ditches nasal COVID vaccine on weak trial data appeared first on.

Vaccination 98

Vaccination Vaccine Trials Immune Response 98

XTalks

FEBRUARY 12, 2021

On the heels of news that AstraZeneca/Oxford’s COVID-19 vaccine has markedly reduced effectiveness against the B.1.351 1.351 variant of SARS-CoV-2 that first appeared in South Africa, the vaccine makers are going full steam ahead to make a variant booster shot against the strain. 1.351 between the vaccine and placebo groups.

Vaccination 105

Vaccination Vaccine Trials Antibody 105

Medical Xpress

DECEMBER 1, 2022

In 2021, a group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate containing an adjuvant, a substance that enhances immune responses, elicited durable neutralizing antibody responses to SARS-CoV-2 (..)

Vaccination 75

Vaccination Vaccine Immune Response Containment 75

Medical Xpress

FEBRUARY 14, 2023

The immune system fights the coronavirus with antibodies and T cells. Scientists have a fairly good idea of how the virus avoids antibodies, including those promoted by vaccination, which is how variants of concern such as the omicron are known to appear.

Antibody 97

Antibody Scientist Vaccination Vaccine 97

Scienmag

DECEMBER 23, 2021

A team led by scientists at Weill Cornell Medicine, Scripps Research and the University of Chicago has identified an important site of vulnerability on influenza viruses—a site that future influenza vaccines and antibody therapies should be able to target to prevent or treat infections by a broad set of influenza strains.

Vaccination 67

Vaccination Vaccine Scientist Antibody 67

Medical Xpress

JANUARY 10, 2025

Scientists from Duke-NUS Medical School and the Singapore General Hospital have discovered that T cellswhite blood cells that can destroy harmful pathogenscan completely prevent viral infection, to an extent previously thought only possible due to neutralizing antibodies.

Antibody 85

Antibody Scientist Development Vaccination 85

pharmaphorum

NOVEMBER 9, 2020

As the death toll from COVID19 inexorably mounts, Pfizer and BioNTech have announced that their COVID-19 vaccine candidate is more than 90% effective at countering the disease in an interim analysis. This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a 2-dose schedule.

Vaccination 98

Vaccination Vaccine Clinical Trials Clinical Trials 98

Medical Xpress

NOVEMBER 10, 2022

Since the COVID-19 pandemic began almost three years ago, scientists have learned that an initial infection can lead to short- and long-term health risks affecting nearly every organ system in the body.

Antibody 102

Antibody Scientist Vaccination Vaccine 102

Pharmaceutical Technology

FEBRUARY 3, 2023

With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more. The field of genomic medicine has reached a true turning point.

Genomics 244

Genomics Genome Medicine Gene Therapy 244

Scienmag

FEBRUARY 25, 2021

Research from the California Institute of Technology shows exactly how antibodies stick to and block the Zika virus, which will inform vaccine development Credit: Image courtesy of Shannon Esswein.

Antibody 52

Antibody Scientist Vaccination Vaccine 52

pharmaphorum

JUNE 29, 2021

Giving one dose each of AstraZeneca and Pfizer COVID-19 vaccines provides good protection against the SARS-CoV-2 virus, but may be associated with more adverse reactions, according to new clinical trial data. The results are available as a preprint and will eventually be published in The Lancet journal.

Immune Response 128

Immune Response Vaccination Vaccine Antibody 128

Scienmag

NOVEMBER 24, 2021

With around 256 million cases and more than 5 million deaths worldwide, the COVID-19 pandemic has challenged scientists and those in the medical field. Researchers are working to find effective vaccines and therapies, as well as understand the long-term effects of the infection.

Vaccination 61

Vaccination Vaccine Antibody Scientist 61

The Pharma Data

DECEMBER 7, 2020

7, 2020 — Scientists say they may be getting closer to creating a universal flu vaccine. In an early-stage clinical trial with 65 volunteers in the United States, an experimental vaccine triggered strong immune responses to a wide range of flu virus strains and subtypes. MONDAY, Dec.

Vaccination 52

Vaccination Vaccine Scientist Immune Response 52

STAT News

OCTOBER 19, 2022

… Moderna disclosed that its Covid-19 vaccine booster targeting the BA.1 1 subvariant of Omicron generated a strong immune response against that variant, with antibody levels staying high for at least three months , Reuters notes. Omicron-tailored 5 targeted vaccine later this year. 5 subvariants of Omicron.

Immune Response 98

Immune Response Scientist Vaccination Vaccine 98

Scienmag

JULY 19, 2022

Yale scientists have developed a novel Omicron-specific mRNA vaccine that offers superior immune protection against two viral subvariants than standard mRNA vaccines. The new vaccine, called Omnivax, increased neutralizing antibody response against the BA.1 New Haven, Conn. The […].

Vaccination 61

Vaccination Vaccine Development Antibody 61

pharmaphorum

AUGUST 12, 2021

A single dose of a monoclonal antibody developed by scientists at the US National Institutes of Health (NIH) has provided protection for people exposed to malaria parasites for up to nine months. The post More malaria hope as antibody protects against infection appeared first on.

Antibody 64

Antibody Vaccination Vaccine Allergies 64

pharmaphorum

FEBRUARY 19, 2021

Two researchers have suggested that the second dose of Pfizer and BioNTech’s COVID-19 vaccine could be delayed, as this would increase the number of people that can be protected while supplies are limited without compromising its efficacy. . Feature image copyright BioNTech SE 2020, all rights reserved.

Scientist 72

Scientist Vaccination Vaccine Antibody 72

pharmaphorum

MARCH 7, 2022

The World Health Organization (WHO) announced the opening of a global biomanufacturing hub located in South Korea to provide training to low- and middle-income countries seeking to produce vaccines and other biologics, such as insulin and monoclonal antibodies. . of individuals in low-income countries have received their first dose.

Vaccination 98

Vaccination Vaccine Manufacturing Production 98

Pharmaceutical Technology

SEPTEMBER 8, 2022

The information contained within the download document is designed for pharmaceutical executives, developers, research scientists and associates, regulatory solutions consultants, and any other individual involved in API biologics production in the pharmaceutical industry.

Gene 100

Gene Marketing Vaccination Vaccine 100

XTalks

JULY 13, 2021

In contrast to antibodies that fight off foreign pathogens, autoantibodies are formed when the body mistakenly reacts to its own tissues and organs. The prevalence of long COVID among fully or partially vaccinated individuals is also not yet known. These include fatigue, shortness of breath, headaches and muscle pain.

Scientist 98

Scientist Research Vaccination Vaccine 98

The Pharma Data

APRIL 18, 2022

The antibodies generated by Pfizer’s COVID-19 vaccine rise more slowly and decline more quickly than those generated by the Moderna vaccine, according to a new study from UVA Health. The researchers determined that both vaccines generated similar peak levels of COVID-fighting antibodies.

Antibody 52

Antibody Vaccination Vaccine Doctors 52

Scienmag

MAY 12, 2021

Scripps Research scientists propose an innovative vaccine approach to protect against a troublesome family of viruses that present a major global health risk LA JOLLA, CA–Scientists at Scripps Research have unveiled a new Ebola virus vaccine design, which they say has several advantages over standard vaccine approaches for Ebola and related viruses (..)

Vaccination 47

Vaccination Vaccine Antibody Scientist 47

Medical Xpress

JANUARY 24, 2023

Scientists have found the "booster" COVID-19 vaccine program led to a large boost in the antibodies that help protect against coronavirus. High levels of antibodies is associated with lower risk of severe infection.

Antibody 73

Antibody Scientist Vaccination Vaccine 73

Scienmag

AUGUST 17, 2020

. — University of Wisconsin-Madison scientists have discovered that a majority of back-pain patients they tested who were taking opioid painkillers produced anti-opioid antibodies. These antibodies may contribute to some of the negative side effects of long-term opioid use.

Antibody 50

Antibody Scientist Vaccination Vaccine 50

Scienmag

JANUARY 10, 2021

January 11, 2021) – To build better vaccines, scientists want to know more about how our bodies make adequate numbers of effective, durable antibodies against the influenza virus. Credit: Kim Ratliff, Augusta University AUGUSTA, Ga.

Vaccination 59

Vaccination Vaccine Antibody Scientist 59

pharmaphorum

AUGUST 7, 2020

The US government has selected a potential vaccine from Sanofi and GlaxoSmithKline for its Operation Warp Speed COVID-19 vaccine development initiative, committing up to $2.1 billion for an initial 100 million doses. The post Coronavirus pharma news roundup – 07/08/20 appeared first on.

Sales 105

Sales Antibody Vaccination Vaccine 105

pharmaphorum

SEPTEMBER 1, 2020

GlaxoSmithKline and US-based Vir Biotechnology are to trial a new therapy for COVID-19 based on an antibody designed to neutralise the SARS-CoV-2 coronavirus. The move brings GSK and Vir into competition with Sanofi and Regeneron, who are developing a cocktail based around two antibodies that could be effective against the virus.

Antibody 59

Antibody Protein Trials Vaccination 59